Summaries of Court Actions are given pursuant to Section 705 of the Federal Food, Drug, and Cosmetic Act. Summaries of Court Actions report cases involving seizure proceedings, criminal proceedings, and injunction proceedings. Seizure proceedings are civil actions taken against goods alleged to be in violation, and criminal and injunction proceedings are against firms or individuals charged to be responsible for violations. The cases generally involve foods, drugs, devices, or cosmetics alleged to be adulterated or misbranded or otherwise violative of the law when introduced into and while in interstate commerce.Summaries of Court Actions are prepared by Food and Drug Division, Office of the General Counsel, HHS, and are published by direction of the Secretary of Health and Human Services.
PRODUCT: Baby Don't Be Bald Medicated Shampoo, Mallard's Tail and Mane Hair and Scalp Treatment, Arthur's Pro-Grow Protein Enriched Conditioning Shampoo Maximum Strength, and other OTC topical preparations, at Mobile, Ala. (S.D.Ala.); Civil No. 95-0339-BH-S.
CHARGED 4-26-95: While held for sale after shipment of one or more of their components in interstate commerce at Mallard Enterprises (a.k.a. Branton Laboratory) and Arthur's Beauty Lab, Inc. (a.k.a. Jessica's Beautee Internationale, Inc.), in Mobile, Ala., the articles were adulterated in that the methods used in, and the facilities and controls used for, their manufacture, processing, packing, and holding did not conform to and were not operated and administered in conformity with current good manufacturing requirements--501(a)(2)(B). The articles were unapproved new drugs--505(a). The articles contained unsafe color additives, for coloring purposes only, which were intended for use in drugs--501(a)(4)(A) and (B). The articles were misbranded in that their labeling failed to bear adequate directions for use--502(f)(1).
DISPOSITION: A default decree of condemnation and destruction ordered the articles destroyed. (F.D.C. No. 67039; S. No. 94-679-282; S.J. No. 2)
PRODUCT: Basmati Rice, Lentils, and Mung Beans, at Elk Grove Village, Ill. (N.D.Ill.); Civil No. 93C-6467.
CHARGED 10-22-93: While held for sale after shipment in interstate commerce at the House of Spices, Inc., in Elk Grove Village, Ill., the articles were adulterated in that they were held under insanitary conditions whereby they might have been contaminated with filth--402(a)(4).
DISPOSITION: Claimant entered into a consent decree, and resumed business upon compliance. (F.D.C. No. 66799; S. No. 94-710-287; S.J. No. 3)
PRODUCT: Liquid Oxygen, at Bloomsberg, Pa. (M.D.Pa.); Civil No. 4:CV-94-0644.
CHARGED 8-17-94: While held for sale after shipment in interstate commerce at Respiratory Support System, Inc., in Bloomsberg, Penn., the articles were adulterated in that the methods used in, and the facilities and controls used for, their manufacture, processing, packing, and holding did not conform to and were not operated and administered in conformity with current good manufacturing requirements--501(a)(2)(B).
DISPOSITION: A consent decree of condemnation ordered the articles destroyed. (F.D.C. No. 66965; S. No. 93-633-774; S.J. No. 5)
PRODUCT: Nifedipine, capsules, at Newark, N.J. (D.N.J.); Civil No. 94-4880 (NHP).
CHARGED 10-14-94: While held for sale after shipment of one or more of their components in interstate commerce at Chase Laboratories in Newark, N.J., the articles were adulterated in that the methods used in, and the facilities and controls used for, their manufacture, processing, packing, and holding did not conform to and were not operated and administered in conformity with current good manufacturing requirements--501(a)(2)(B). The articles were also unapproved new drugs introduced into interstate commerce--505(a).
DISPOSITION: A consent decree of condemnation was filed, and all but eight lots of the articles were destroyed. The claimant was permitted to attempt to bring these lots into compliance. Four lots were authorized for release, and the others were destroyed. (F.D.C. No. 66914; S. No. 93-675-794; S.J. No. 6)
FDA Consumer magazine (May 1996)